Kutlin A, Roblin PM, Reznik T, Hammerschlag MR; Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 671 (abstract no. 986).
SUNY Health Sci. Ctr. at Brooklyn, Brooklyn, NY, USA
BACKGROUND: Chronic infections with Cpn have been implicated in the development of atherosclerosis. Several antibiotic treatment trials on the prevention of secondary cardiovascular events in CAD patients are under the way. In this study we investigated the effect of AZ on viability of Cpn and production of the inflammatory cytokines in a continuous culture model.METHODS: Continuously infected HEp-2 cells with TW183 and CM-1 has been maintained over 2-2.5 years without centrifugation, addition of cycloheximide or fresh cells. These cells were plated onto 24-well plates and incubated at 35[0]C for 1-6 d with and without AZ at final concentrations of 0.125 (MIC[90]), 0.25 and 0.5 ug/ml. Cells and supernatants were tested daily. IL-1beta, IL-4, IL-6, IL-10 and IFN-g were assayed by sandwich ELISA.RESULTS: We found that 6-day treatment of continuously infected cells with AZ reduced IFU from 10[6]-10[7]/ml to 10[2]-10[3]/ml. We found no changes in the MIC or MBC of Cpn after 6 days exposure to 0.5 ug/ml of AZ. Detectable levels (pg/ml) of all assayed cytokines were present in continuously infected cells as shown below [table: see text].CONCLUSION: AZ at concentrations of 4x MIC reduced but did not eliminate Cpn in continuously infected cells. AZ had no apparent effect on cytokine production. This may be an important observation, as prolonged treatment with AZ, as being done in the secondary prevention trials, may not eradicate Cpn.
Publication Types:
Keywords:
- Anti-Bacterial Agents
- Atherosclerosis
- Azithromycin
- Chlamydia Infections
- Chlamydophila pneumoniae
- Communicable Diseases
- Cytokines
- Humans
- Infection
- Interleukin-1
- Interleukin-10
- Interleukin-6
- Microbial Sensitivity Tests
- Models, Biological
Other ID:
UI: 102246310
From Meeting Abstracts